Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.
CTCL
HDAC inhibitors
bexarotene
interferon
targeted therapy
topical formulation
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
02 Feb 2021
02 Feb 2021
Historique:
received:
10
11
2020
revised:
27
01
2021
accepted:
28
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.
Identifiants
pubmed: 33540765
pii: pharmaceutics13020200
doi: 10.3390/pharmaceutics13020200
pmc: PMC7913115
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 18lm0203062h0001
Références
Dermatol Ther. 2020 Nov;33(6):e14099
pubmed: 32725764
Leuk Lymphoma. 2013 Mar;54(3):514-9
pubmed: 22891708
Dermatol Clin. 2015 Oct;33(4):731-45
pubmed: 26433845
Am J Hematol. 2007 Sep;82(9):792-7
pubmed: 17546636
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
J Clin Oncol. 2001 May 1;19(9):2456-71
pubmed: 11331325
Case Rep Oncol. 2018 Jan 16;11(1):29-32
pubmed: 29515406
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Hematology. 2015 Oct;20(9):538-42
pubmed: 25592781
Arch Dermatol. 2002 Mar;138(3):325-32
pubmed: 11902983
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e72-e74
pubmed: 30102807
Front Med (Lausanne). 2019 Aug 13;6:181
pubmed: 31457014
J Dermatol. 2020 May;47(5):443-451
pubmed: 32189402
Front Med (Lausanne). 2019 Jul 31;6:174
pubmed: 31417907
Arch Dermatol. 2003 Feb;139(2):165-73
pubmed: 12588222
J Dermatol. 2017 Feb;44(2):135-142
pubmed: 27543197
J Am Acad Dermatol. 2004 Apr;50(4):600-7
pubmed: 15034511
Arch Dermatol. 2008 Jun;144(6):727-33
pubmed: 18559761
Leuk Lymphoma. 2009 Dec;50(12):1969-76
pubmed: 19860617
J Clin Oncol. 1990 Jan;8(1):155-60
pubmed: 2295906
Br J Haematol. 2009 Apr;145(2):173-9
pubmed: 19236377
Br J Dermatol. 2014 Mar;170(3):720-4
pubmed: 24438061
Hematol Oncol Clin North Am. 2019 Feb;33(1):103-120
pubmed: 30497668
JAMA Dermatol. 2013 Jan;149(1):25-32
pubmed: 23069814
Dermatol Ther. 2003;16(4):299-302
pubmed: 14686972
Eur Rev Med Pharmacol Sci. 2018 Jun;22(11):3586-3594
pubmed: 29917213
J Clin Oncol. 1998 Jan;16(1):27-34
pubmed: 9440719
Indian J Dermatol. 2016 Jan-Feb;61(1):119
pubmed: 26955126
J Dermatol. 2019 Jul;46(7):557-563
pubmed: 31090237
J Dermatol Sci. 2016 Sep;83(3):182-9
pubmed: 27342040
Cancer. 2002 Aug 1;95(3):569-75
pubmed: 12209749
J Am Acad Dermatol. 2004 Mar;50(3):375-9
pubmed: 14988678
N Engl J Med. 1987 Feb 5;316(6):297-303
pubmed: 3543674
J Clin Oncol. 2015 Nov 10;33(32):3750-8
pubmed: 26195720
J Clin Invest. 2012 Feb;122(2):575-85
pubmed: 22251703
Br J Dermatol. 2013 Jan;168(1):192-200
pubmed: 22963233
Clin Lymphoma Myeloma. 2006 Jul;7(1):51-8
pubmed: 16879770
Am J Hematol. 2011 Mar;86(3):325-7
pubmed: 21328438
J Clin Oncol. 2010 Apr 10;28(11):1870-7
pubmed: 20212249
Anticancer Res. 2017 Jul;37(7):3461-3471
pubmed: 28668835
Front Oncol. 2019 Apr 11;9:260
pubmed: 31032224
J Am Acad Dermatol. 2003 Nov;49(5):873-8
pubmed: 14576667
J Clin Oncol. 2020 Jan 1;38(1):20-28
pubmed: 31532724
Ann Oncol. 2017 Oct 1;28(10):2517-2525
pubmed: 28961843
Br J Dermatol. 2016 Jul;175(1):80-8
pubmed: 26836950
J Dermatol. 2018 Apr;45(4):e84-e85
pubmed: 29068082
Front Med (Lausanne). 2018 Aug 27;5:236
pubmed: 30211164
Int J Dermatol. 2003 Jan;42(1):53-6
pubmed: 12581145
Blood. 2012 May 3;119(18):4115-22
pubmed: 22394596
JAAD Case Rep. 2020 Jun 04;6(8):761-765
pubmed: 32728607
Cancer. 2005 Dec 1;104(11):2437-41
pubmed: 16216001
J Natl Compr Canc Netw. 2020 May;18(5):522-536
pubmed: 32380458
Front Oncol. 2019 Sep 20;9:907
pubmed: 31616630
Exp Dermatol. 2016 Feb;25(2):107-12
pubmed: 26441016
Life (Basel). 2020 Sep 16;10(9):
pubmed: 32948031
Dermatol Ther. 2003;16(4):311-21
pubmed: 14686974
Leuk Lymphoma. 2003 Jun;44(6):1027-35
pubmed: 12854905
J Am Acad Dermatol. 2020 Sep;83(3):928-930
pubmed: 32089294
J Clin Oncol. 2007 Jul 20;25(21):3109-15
pubmed: 17577020
Nat Rev Clin Oncol. 2010 Aug;7(8):430-2
pubmed: 20668480
Int J Dermatol. 2017 Dec;56(12):1400-1405
pubmed: 28762479
Br J Dermatol. 2008 Jun;158(6):1256-63
pubmed: 18363755
J Invest Dermatol. 2015 Aug;135(8):2102-2108
pubmed: 25826424
J Clin Oncol. 2009 Nov 10;27(32):5410-7
pubmed: 19826128
Dermatol Ther. 2020 Jul;33(4):e13487
pubmed: 32362053
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33243932
J Dermatol. 2014 Jan;41(1):50-6
pubmed: 24354781
Clin Cancer Res. 2002 May;8(5):1234-40
pubmed: 12006543
Br J Dermatol. 2012 May;166(5):948-52
pubmed: 22233400
Curr Hematol Malig Rep. 2020 Feb;15(1):9-19
pubmed: 32016790
Clin Cancer Res. 2017 Jul 15;23(14):3552-3556
pubmed: 28167509
J Dermatol. 2020 Jun;47(6):636-640
pubmed: 32207181
J Clin Oncol. 2016 Nov 1;34(31):3733-3739
pubmed: 27354476
Cancer Res. 1977 May;37(5):1450-4
pubmed: 851960
Br J Haematol. 2017 Apr;177(2):287-310
pubmed: 28220931
Blood. 2015 Jan 1;125(1):71-81
pubmed: 25336628
J Dermatol. 2017 Mar;44(3):e13-e14
pubmed: 27440178
JAMA Dermatol. 2015 Jan;151(1):73-7
pubmed: 25317818
J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2
pubmed: 24438970
J Dermatolog Treat. 2017 Sep;28(6):567-569
pubmed: 28635518